UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarterly Period Ended ~~March~~June 3130, 2022

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition period from ______________to ______________

Commission File Number: 000-50099

GRAPEFRUIT USA, INC.

(Exact name of registrant as specified in its charter)

delaware		95-4451059
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1000 Northwest Street, Mid-Town Brandy Wine, Suite 1200-3094, Wilmington, DE 19801

(Address of principal executive offices) (Zip Code)

310-575-1175

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol(s) Name of exchange on which registered No par value common stock GPFT OTCQB

Title of each class		Trading symbol(s)		Name of exchange on which registered
Common Stock, $0.0001 par value		GPFT		OTCQB

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.0001 par value

Common Stock, $0.0001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒

No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒

No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One).

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐

No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

As of ~~May~~August 2011, 2022, the number of shares outstanding of the registrant’s class of common stock was ~~559~~600,~~512~~293,~~622~~195.

TABLE OF CONTENTS

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements	4
	Condensed Consolidated Balance Sheets at March 31,2022 (Unaudited) and December 31, 2021 (Audited)	4
	Condensed Consolidated Balance Sheets at June 30,2022 (Unaudited) and December 31, 2021 (Audited)	4
	Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	5
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 (Unaudited)	6
	Condensed Consolidated Statement of Stockholders’ Deficit for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	7
	Condensed Consolidated Statement of Stockholders’ Deficit for the Six Months Ended June 30, 2022 and 2021 (Unaudited)	7
	Notes to Condensed Consolidated Financial Statements (Unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2123
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2427
Item 4.	Controls and Procedures	2427
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	2527
Item 1A.	Risk Factors	2527
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2527
Item 3.	Defaults Upon Senior Securities	2527
Item 4.	Mine Safety Disclosures	2527
Item 5.	Other Information	2527
Item 6.	Exhibits	2528
SIGNATURES		2629

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, plans and objectives of management and markets for our common stock are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our most recent Annual Report on Form 10-K and any updates described in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the reports we file with the SEC, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors in our SEC reports could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2022 (Unaudited)			December 31, 2021 (Audited)
	June 30, 2022 (Unaudited)			December 31, 2021 (Audited)
ASSETS
CURRENT ASSETS:
Cash	$	5,~~153~~035		$	9,095
Accounts receivable		~~278~~22,~~356~~379			278,422
Inventory		~~383~~339,~~239~~312			389,282
Licensee agreement		3024,~~800~~200			37,400
Other		3,429			-
Operating right of use - asset - current portion		12,582			53,123
Total current assets		700,977			714,199
Other		1,143			-
Total current assets		404,651			767,322
NON-CURRENT ASSETS:
Property, plant and equipment, net		1,~~745~~725,~~932~~261			1,769,627
Operating right of use - assets		513,~~299~~346			7421,~~886~~763
Goodwill		250,000			250,000
Intangible asset		250,000			250,000
Other		7,459			7,459
TOTAL ASSETS	$	2,~~755~~390,~~667~~717		$	2,816,171
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Notes payable	$	~~302~~313,~~943~~050		$	262,839
Accrued loan interest		1,170,617			1,044,612
Accrued loan interest – nonrelated parties		876,887			1,014,653
Related party payable		992,601			702,581
Accrued loan interest – related parties		83,067			29,959
Legal settlements - current portion		513,370			541,697
Related party payable		1,265,826			702,581
Subscription payable		251,220			251,727
Legal settlements - current portion		530,388			541,697
Derivative liability		9,960			127,392
Subscription payable		389,823			251,727
Capital lease - current portion		22,591			31,166
Derivative liability		3,498			127,392
Operating right of use - liability - current portion		33,265			65,486
Capital lease - current portion		18,964			31,166
Convertible notes (net of discount of $179,755 and $325,089, respectively)		3,786,293			3,640,959
Operating right of use - liability - current portion		12,582			65,486
Accounts payable and accrued expenses		1,014,108			1,035,114
Convertible notes (net of discount of $90,043 and $325,089, respectively)		2,676,005			3,640,959
Total current liabilities		8,096,968			7,703,573
Accounts payable and accrued expenses		1,111,398			1,035,114
Capital lease		1,928			7,669
Total current liabilities		7,281,488			7,703,573
Operating right of use - liability		18,882			11,097
Capital lease		-			7,669
Long-term notes payable, net		909,545			908,617
Operating right of use - liability		3,346			11,097
Total long-term liabilities		930,355			927,383
Long-term notes payable, net		910,411			908,617
TOTAL LIABILITIES		9,027,323			8,630,956
Total long-term liabilities		913,757			927,383
TOTAL LIABILITIES		8,195,245			8,630,956
STOCKHOLDERS’ DEFICIT
Common stock ($0.0001 par value, 1,000,000,000 shares authorized; 559,512,622 and 557,162,744 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively)		55,951			55,716
Common stock ($0.0001 par value, 1,000,000,000 shares authorized; 585,293,195 and 557,162,744 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively)		58,529			55,716
Preferred stock ($0.0001 par value, 1,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021)		-			-
Preferred stock ($0.0001 par value, 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021)		-			-
Additional paid in capital		1012,~~989~~819,~~946~~736			10,962,797
Accumulated deficit		(1718,~~310~~675,~~419~~659	)		(16,826,164	)
Total stockholders’ deficit		(65,~~264~~797,~~522~~394	)		(5,807,651	)
Noncontrolling interest		(7,134	)		(7,134	)
Total deficit		(65,~~271~~804,~~656~~528	)		(5,814,785	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	2,~~755~~390,~~667~~717		$	2,816,171

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three months ended			Three months ended			Six months ended			Six months ended
	March 31, 2022			March 31, 2021
	June 30, 2022			June 30, 2021			June 30, 2022			June 30, 2021
Revenue	$	524,~~650~~062		$	~~350~~82,~~815~~489		$	29,711		$	433,304
Cost of goods sold		71162,~~861~~450			~~423~~157,~~435~~163			234,311			580,598
Gross profit (loss)		(66,211	)		(72,620	)
Gross (loss) profit		(138,388	)		(74,674	)		(204,600	)		(147,294	)
Operating expenses:
Sales		~~566~~-			3(1,~~596~~636	)		-			1,960
Stock option expense		14,990			-
General and administrative		727,976			529,246			967,515			930,658
General and administrative		223,984			401,412
Total operating expenses		727,976			527,610			967,515			932,618
Total operating expenses		239,540			405,008
Loss from operations		(866,364	)		(602,284	)		(1,172,115	)		(1,079,912	)
Loss from operations		(305,751	)		(477,628	)
Other income (expense):
Other income (expense):
Interest expense		(477,745	)		(448,996	)		(773,681	)		(870,377	)
Interest expense		(295,936	)		(421,381	)
Change in value of derivative instruments		6,462			136,652			123,894			77,333
Change in value of derivative instruments		117,432			(59,319	)
Gain (loss) on extinguishment of debt		(27,593	)		60,000			(27,593	)		(398,373	)
Gain (loss) on extinguishment of debt		-			(458,373	)
Loss on extinguishment of debt - related parties		-			(491,998	)		-			(491,998	)
Total other income (expense)		(178,504	)		(939,073	)
Total other expense		(498,876	)		(744,342	)		(677,380	)		(1,683,415	)
Loss before income taxes		(484,255	)		(1,416,701	)
(Loss) income before income taxes		(1,365,240	)		(1,346,626	)		(1,849,495	)		(2,763,327	)
Tax provision		-			-			-			-
Net loss		(484,255	)		(1,416,701	)
Net (loss) income	$	(1,365,240	)	$	(1,346,626	)	$	(1,849,495	)	$	(2,763,327	)
Loss attributable to noncontrolling interest		-			-
Net loss per share – Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Net loss attributable to Grapefruit USA, Inc.	$	(484,255	)	$	(1,416,701	)
Weighted average common stock outstanding - Basic and diluted		559,514,158			518,864,169			561,807,925			521,811,303
Net loss per share - Basic and diluted	$	(0.00	)	$	(0.00	)
Weighted average common stock outstanding - Basic and diluted		560,910,403			508,357,473

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three months ended			Three months ended
	Six months ended			Six months ended
	March 31, 2022			March 31, 2021
	June 30, 2022			June 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(~~484~~1,~~255~~849,495	)	$	(12,~~416~~763,~~701~~327	)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation expense		23,695			22,629
Depreciation and amortization expense		44,366			46,113
Amortization/acquisition of right of use asset		144,485			237,226
Amortization of debt discount		240,446			463,217
Change in value of derivative		(~~117~~123,~~432~~894	)		59(77,~~319~~333	)
Loss on issuance of warranty		-			235,103
Loss on extinguishment of debt - related parties		-			491,998
Stock-based compensation for services		729			9,407
Loss on extinguishment of debt		-			398,373
Stock option expense		14,990			-
Stock-based compensation for services		195,905			239,044
(Gain) Loss on extinguishment of debt		-			654,693
Interest expense		315,335			-
Non-cash interest		76,063			-
Stock option expense		20,998			32,877
Changes in operation assets and liabilities:					-
Loss on bad debts		250,054			-
Accounts Receivables		66			(206,435	)
Loss on legal settlement		36,462			-
Inventory		6,043			11,299
Loss on inventory valuation		68,941			-
Prepaid expense and current assets		3,171			32,471
Changes in operation assets and liabilities:
Right-of-use assets		23,587			22,947
Accounts Receivables		5,989			(188,730	)
Accounts payable		(21,006	)		(35,231	)
Inventory		(18,970	)		(38,185	)
Accrued expenses and other current liabilities		(29,071	)		-
Prepaid expense and current assets		12,057			(26,384	)
Accrued loan interest expense		126,005			134,980
Right-of-use assets		58,959			46,269
Right-of-use liability		(24,436	)		(22,738	)
Accounts payable		76,283			(4,000	)
Net cash used for used for operating activities		(257,366	)		(261,031	)
Accrued executive compensation		300,000			-
Accrued expenses and other current liabilities		-			337,792
Accrued loan interest expense		145,825			280,964
Right-of-use liability		(60,655	)		(45,852	)
Net cash (used for)/provided by used for operating activities		(281,394	)		(807,164	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of land and equipment		-			(3056,~~521~~679	)
Net cash used for investing activities		-			(3056,~~521~~679	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal repayment of capital lease liability		(1419,~~316~~871	)		(1531,~~577~~915	)
Repayment of legal liability		(2012,~~612~~645	)		(~~136~~18,000	)
Proceeds from convertible notes, net		-			~~398~~450,000
Repayment of loans, net		-			(1,568	)
Proceeds from loans, net		50,000			-
Repayment of loan principal		(13,~~668~~395	)		(3,162	)
Proceeds from related parties		290,020			187,792
Proceeds from related party notes		263,245			30,180
Net cash proceeds from financing activities		253,424			432,647
Proceeds from exercise of warrants		-			250,000
NET INCREASE (DECREASE) IN CASH		(3,942	)		141,095
Proceeds from sale of common stock		-			75,000
Net cash proceeds from financing activities		277,334			752,103
NET INCREASE (DECREASE) IN CASH		(4,060	)		(111,740	)
CASH, BEGINNING BALANCE		9,095			299,895
CASH, ENDING BALANCE	$	5,~~153~~035		$	~~440~~188,~~990~~155
SUPPLEMENTAL DISCLOSURE ON CASH FINANCING ACTIVITY
SUPLEMENTAL DISCLOSURE ON CASH FINANCING ACTIVITY
Cash paid for interest expense		4659,~~504~~992			3277,~~667~~467
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING ACTIVITY
SUPLEMENTAL DISCLOSURE ON NON-CASH FINANCING ACTIVITY
Shares issued for legal settlement		1135,~~664~~127			-1,090,462
Shares issued for conversion of notes payable		-1,745,818			51996,~~667~~620
Shares issued for compensation		514			67,420
Shares issued for debt settlement with related parties		-			699,236
Shares issued for compensation		57,514			-
Stock open compensation		20,998			-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

GRAPEFRUIT USA, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)

	Shares		Amount		Capital		Deficit			Deficit			Interest			Deficit
	Deficit Attributable to Grapefruit USA, Inc.
	Common Stock				Additional					Total			Non-
	Number of				Paid in		Accumulated			Stockholders’			controlling			Total
	Shares		Amount		Capital		Deficit			Deficit			Interest			Deficit
Balance as of December 31, 2020		505,700,437	$	50,570	$	6,591,177	$	(11,321,494	)	$	(4,679,747	)	$	-		$	(4,679,747	)
Shares issued for services		16,~~399~~349,937		~~140~~635		55249,~~804~~429		-			55250,~~944~~064			-			55250,~~944~~064
Shares issued for settlement		18,~~666~~404,~~667~~186		~~167~~840		511,~~500~~089,620		-			511,~~667~~090,460			-			511,~~667~~090,460
Shares issued upon warrant exercise		2,000,000		200		249,800		-			250,000			-			250,000
Net loss		-		-		-		(1,416,701	)		(1,416,701	)		-			(1,416,701	)
Shares issued for note conversion		13,352,264		1,335		995,285		-			996,620			-			996,620
Balance as of March 31, 2021		510,767,041	$	51,077	$	6,948,281	$	(12,738,195	)	$	(5,738,837	)	$	-		$	(5,738,837	)
Shares issued for related party		11,710,465		1,171		1,190,063		-			1,191,234			-			1,191,234
Stock options granted pursuant to board of director agreement		-		-		32,877		-			32,877			-			32,877
Shares issued for purchase of stock		1,000,000		100		74,900		-			75,000			-			75,000
Net loss		-		-		-		(2,763,327	)		(2,763,327	)		-			(2,763,327	)
Balance as of June 30, 2021		548,517,289	$	54,851	$	10,473,151	$	(14,084,821	)	$	(3,556,819	)	$	-		$	(3,556,819	)
Balance as of December 31, 2021		557,162,744	$	55,716	$	10,962,797	$	(16,826,164	)	$	(5,807,651	)	$	(7,134	)	$	(5,814,785	)
Shares issued for services		242,527,000		2253		~~727~~57,556		-			~~729~~57,809			-			~~729~~57,809
Shares issued for settlement		2,325,878		233		1134,~~432~~894		-			1135,~~665~~127			-			1135,~~665~~127
Stock options granted pursuant to board of director agreement				-		14,990		-			14,990			-			14,990
Shares issued for note conversion		23,277,573		2,327		1,743,491		-			1,745,818			-			1,745,818
Net loss		-		-		-		(484,255	)		(484,255	)		-			(484,255	)
Stock options granted pursuant to board of director agreement				-		20,998		-			20,998			-			20,998
Balance as of March 31, 2022		559,512,622	$	55,951	$	10,989,946	$	(17,310,419	)	$	(6,264,522	)	$	(7,134	)	$	(6,271,656	)
Net loss		-		-		-		(1,849,495	)		(1,849,495	)		-			(1,849,495	)
Balance as of June 30, 2022		585,293,195	$	58,529	$	12,819,736	$	(18,675,659	)	$	(5,797,394	)	$	(7,134	)	$	(5,804,528	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

GRAPEFRUIT USA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH~~June 3130, 2022

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS

Overview

Grapefruit Boulevard Investments, Inc. (“we”, “our”, “us”, “Grapefruit”, “GBI”, or “the Company”) was formed as a California corporation on August 28, 2017 and began operation in September 2017. On July 10, 2019, Grapefruit acquired Imaging3, Inc. (“IGNG”) in a reverse acquisition (the “Acquisition”). Under the terms of a Share Exchange Agreement by and among IGNG, Grapefruit and Grapefruit’s shareholders, IGNG issued to Grapefruit’s existing shareholders approximately 81% of the post-Acquisition IGNG common shares and the IGNG shareholders retained 19% of the post-Acquisition IGNG common shares. As a result, our financial statements are prepared using the acquisition method of accounting with Grapefruit as the accounting acquirer and IGNG treated as the legal acquirer and accounting acquiree. On December 16, 2019, Grapefruit filed the necessary paperwork with the Financial Industry Regulatory Authority (“FINRA”) and OTC Markets to effect the Company Name and Ticker symbol changes from “IGNG” to “GPFT” formally changing our corporate name from Imgaing3, Inc. to Grapefruit USA, Inc., a Delaware corporation whose stock is trading under the Ticker Symbol “GPFT”.

The Company’s annual distribution licensure renews again on June 13, 2023. Our annual manufacturing license was renewed by the California Department of Health. Grapefruit has not yet applied for a license to cultivate cannabis flowers, and will not until construction of our cultivation facility has been substantially completed. We own two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park where we intend to build a 30,000 square foot fully licensed cannabis facility as more fully described below. The location within Coachillin’ allows the Company to apply for and hold every cannabis license available under the California Cannabis laws.

The “Mothership” Cultivation & Lab Facility

In July 2021, Grapefruit obtained a development permit to build a 30,000 square foot “Mothership” facility intended to house a state-of-the-art indoor grow as well as a separately licensed distribution hub and laboratory that will produce the patented Hourglass line of topical creams as well as high quality extracts from trim generated by processing the indoor cannabis flowers. We intend to obtain CGMP certification for the lab pursuant to the Good Manufacturing Practice regulations enforced by the Federal Drug Administration (“FDA”). We expect that our facility will meet proper design, monitoring, and manufacturing control processes to assure the strength, quality, and purity of all Hourglass products we manufacture. We anticipate the FDA to mandate all cannabis facilities to be CGMP certified to continue in operation if cannabis becomes legalized by the federal government.

Summit Boys

In August 2021, the Company purchased control of Summit Boys, Inc., a cannabis extraction brand with product lines in retail stores throughout the State of California. The Company is continuing the Summit Boys’ business without interruption and is currently selling its branded products in California through Grapefruit.

Summit Boys’ premium extracts include sugar, crumble, badder, live resin, diamonds, budder, sauce, caviar and other extracted cannabis products, which are currently placed in licensed dispensaries throughout California and are protected by United States of America Trademark Reg. No. 6406802, July 6, 2021.

Grapefruit’s Business ~~Competitive Advantage in the Industry~~Development

In December 2020, we shifted our corporate focus from distribution operations to further development of our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream. Hourglass is the first and only patented Full Spectrum THC+ Cannabinoid Topical delivery Cream that provides its users with a full body, synergistic entourage effect that was previously only available by smoking, vaping or eating cannabis products such as cannabis flowers and gummies. Our Topical Cream is scientifically designed to deliver the full effects of THC combined with a broad range of cannabinoids for a user’s overall health, wellness, and well-being. Hourglass products are laboratory tested. Test results published on every package via a designated QR Code. There is no other topical cream product on the market with our patented technology that provides users with the holistic benefits of the entourage effect of THC+CBD, CBN, CBG, Delta8, THCV and CBE. Hourglass™ is currently available in licensed retail and mobile cannabis dispensaries in Central California and Los Angeles County, California, USA. Hourglass™ is not intended for use to cure, mitigate, treat, or prevent disease and we are not making any such claims.

In July ~~2022~~2021, we decided to bring our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to the federally legalized Canadian cannabis marketplace. In January 2022, the company’s licensed Canadian distribution partner Medz Cannabis filed a Notice of New Cannabis Product (“NNCP”) with Health Canada on Grapefruit’s behalf for its Hourglass THC+CBD Topical cream. Health Canada is the Canadian federal government department that is responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. Under Canada’s Federal Cannabis Regulatory scheme, Health Canada must be notified of a company’s intent to sell a cannabis product that has not previously been sold in the country.

On March 21, 2022, Health Canada approved the Company’s NNCP application authorizing Grapefruit to sell its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to licensed retail outlets throughout Canada under NNCP ID No. NP-V2EHUWO907.

In March 2022, we expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.

Grapefruit holds its State of California annual licensing from the Bureau of Cannabis Control and the California Department of Public Health. The Company has a permanent annually renewable license as opposed to a provisional or temporary one. The Company is one of the earliest registered distribution companies in the State of California to have an annually renewable license as opposed to the provisional licenses previously granted.

Grapefruit operates within the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park (the “Park”), located in Desert Hot Springs, California, 14 miles north of downtown Palm Springs. The Park is the first and largest cooperative canna-business compound of its kind. It is unique in that the landowners each own a proportionate interest in a collaborative owner’s association, which allows them to share much of the park overhead such as clean cultivation water, park security and access to agricultural power rates.

Distribution

In early 2021, the Company temporarily suspended its ‘bulk’ purchase and distribution of wholesale cannabis flower due to negative market forces in the wholesale cannabis market beyond the control of the Company. The Company can and will resume wholesale ‘bulk’ cannabis sales and distribution operations when market forces indicate such resumption is appropriate. Nonetheless, the Company continues to distribute ‘bulk’ concentrates to support our Summit Boys brand in California. onIn March go2022, ~~forward~~we ~~basis~~expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.

Manufacturing

The Company owns a fully licensed ethanol extraction facility in the City of Desert Hot Springs, CA. The Company owns and operates a Type 6 Ethanol Extraction Plant which removes the essential cannabis compounds, such as THC Distillate, that we, and others use, to produce cannabis products.

Grapefruit manufactures its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream at its Coachillin’ facility which allows us to maintain strict quality control standards. In addition, Grapefruit’s extraction lab produces high quality distillate or “Honey Oil” from cannabis trim sourced by Grapefruit. THC Honey Oil is a fundamental cannabis commodity which serves as the active ingredient in products from infused edibles to tinctures/creams. Grapefruit chose to set up its extraction laboratory in the City of Desert Hot Springs because, among other factors, the ~~City~~city does not tax the manufacture of oil by Grapefruit at its Desert Hot Springs extraction facility, thereby providing Grapefruit with an additional competitive advantage.

Binding Letter of Intent to Acquire Diagnostic Lab Corporation

On March 22, 2022, the Company entered into a Memorandum of Understanding with Diagnostic Lab Corporation, Inc., a Delaware corporation (“DLC”). On June 30, 2022, the Company entered into a Binding Letter of Intent (“LOI”) with DLC. Pursuant to the LOI, the Company will acquire the assets of DLC, its IP and all of its affiliated entities for a combination of cash and a to-be-determined number of the Company’s $0.0001 par value common stock. The Company and DLC will jointly recapitalize the Company by raising $12.5 million (inclusive of a currently committed $5.5 million debt facility) which will enable the Company to construct its Good Manufacturing Practices (“cGMP”) certified Desert Hot Springs, CA, Coachillin Park. The “Mothership” facility which will house a state-of-the-art indoor cultivation, manufacturing laboratory and distribution facility. In addition, the recapitalization will fund the Company’s Hourglass 510K Project, the Medical Study of the effects of Hourglass powered products on osteoarthritis sufferers and afford sufficient working capital and interest payment reserves to allow the post-transaction Company to reach positive cash flow. As of August 20, 2022, the Company is in the process of finalizing its due diligence on DLC and is in the final stages of negotiating the terms of its anticipated financing and structuring of the transaction documents.

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

The audited financial statements as of December 31, 2021 and December 31, 2020, and for the year ended December 31, 2021 and December 31, 2020, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. They do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes filed with the SEC for the year ended December 31, 2021.

~~Basis~~The audited consolidated financial statements as of ~~Consolidation~~December –31, ~~Subsidiaries~~2021 ~~are~~and ~~entities~~December ~~controlled~~31, by2020, and for the ~~Company.~~year ~~Control~~ended ~~exists~~December ~~when~~31, 2021 and December 31, 2020, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s ~~either~~financial ~~has~~position, aresults ~~controlling~~of ~~voting~~operations ~~interest~~and orcash isflows for the ~~primary~~periods ~~beneficiary~~shown. The results of operations for such periods are not necessarily indicative of the results expected for a ~~variable~~full ~~interest~~year ~~entity~~or for any future period. ~~The~~They ~~financial~~do ~~statements~~not include all of ~~subsidiaries~~the ~~are~~information and ~~included~~footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the ~~consolidated~~Company’s audited financial statements ~~from~~and ~~the~~notes ~~date~~filed ~~that~~with ~~control~~the ~~commences~~SEC ~~until~~for the ~~date~~year ~~that~~ended ~~control~~December ~~ceases~~31, 2021.

InBasis ~~August~~of ~~2021,~~Consolidation ~~the~~– ~~Company~~Subsidiaries ~~entered~~are ~~into~~entities acontrolled ~~Stock~~by ~~Purchase Agreement acquiring~~ the ~~majority~~Company. ~~ownership~~Control ~~and~~exists ~~control~~when ofthe ~~Summit~~Company either ~~Boys,~~has ~~Inc.,~~ a ~~very~~ ~~well-known~~controlling ~~and~~voting ~~established~~interest ~~cannabis~~or ~~extraction~~is ~~brand~~the ~~with~~primary ~~product~~beneficiary ~~lines~~of ina ~~retail~~variable ~~stores~~interest ~~throughout the State of California~~entity. The ~~Company~~ ~~plans~~financial onstatements ~~continuing~~of subsidiaries ~~the~~are ~~business~~included ~~without~~in ~~interruption and plans on licensing~~ the ~~Summit~~consolidated ~~Boys~~financial ~~brand~~statements infrom the ~~State~~date ~~of Oklahoma under~~ that ~~State’s~~control ~~newly~~commences ~~enacted~~until ~~legalized~~the ~~statutory~~date ~~scheme~~that ~~for cannabis products~~control ceases. ~~This~~All ~~non-~~significant ~~and~~intercompany ~~non-operating~~transactions ~~subsidiary has~~are ~~been consolidated with Grapefruit’s financial statements~~eliminated. ~~As consideration, the Company issued 4,545,455 shares of common stock for 51% ownership if Summit Boys, Inc.~~

In August 2021, the Company entered into a Stock Purchase Agreement acquiring the majority ownership and control of Summit Boys, Inc., a very well-known and established cannabis extraction brand with product lines in retail stores throughout the State of California. The Company plans on continuing the business without interruption and plans on licensing the Summit Boys brand in the State of Oklahoma under that State’s newly enacted legalized statutory scheme for cannabis products. This non-significant and non-operating subsidiary has been consolidated with Grapefruit’s financial statements. As consideration, the Company issued 4,545,455 shares of common stock for 51% ownership if Summit Boys, Inc. There was no activity for the six months ended June 30, 2022.

Segments – We have two reporting segments: Retail and Wholesale. For the three months ended June 30, 2022, we generated 94.4% of our total revenues from our retail segment and 5.6% of our total revenues from our wholesale segment. For the three months ended June 30, 2021, we generated 5.0% of our total revenues from our retail segment and 95.0% of our total revenues from our wholesale segment. For the six months ended June 30, 2022, we generated 84.3% of our total revenues from our retail segment and 15.7% of our total revenues from our wholesale segment. For the six months ended June 30, 2021, we generated 1.0% of our total revenues from our retail segment and 99.0% of our total revenues from our wholesale segment.

Our retail operations generate revenue primarily through the sale of our Summit Boys branded product, THC “Honey Oil” tinctures, and CBD-Infused Hourglass™ Topical Cream products through our online and third-party sales channels. Our wholesale revenues are generated from the sales of our THC-Infused Hourglass™ Topical Cream, RSO syringes, vape cartridges, and flower products through our pre-existing and newly acquired customers.

Financial information about our business segments and geographical areas is provided in Note 14, Segment Information, to our consolidated financial statements in Part I, Item 1, “Notes to Condensed Consolidated Financial Statements (Unaudited),” in this Quarterly Report on Form 10-Q.

Use of Estimates – The preparation of our financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our financial statements and the reported amounts of revenues and expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. The company’s most significant estimates related to useful life for depreciation, the value of long-lived assets and related impairment, and provision for income taxes of property and equipment.

~~Inventory – Inventory is comprised of raw material, work in process and finished goods. The following sets forth selected items from our inventory as of March 31, 2022 and December 31, 2021:~~10

~~SCHEDULE~~Inventory – OFInventory ~~INVENTORY~~is valued at the lower of cost and net realizable value, determined using weighted average cost. All direct and indirect costs related to inventory are capitalized as they are incurred, and they are subsequently recorded in cost of goods sold on the statements of loss and comprehensive loss at the time inventory is sold. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company’s estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management’s estimates and such differences could be material to the Company’s statements of financial position, statements of loss and comprehensive loss and statements of cash flows. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,941 reduction in inventory. Most of the product was salvageable and will be ready for resale in August 2022.

	March 31, 2022		December 31, 2021
Raw material	$	298,722	$	304,331
Work in process		-		-
Finished goods		84,517		84,951
Total inventory	$	383,239	$	389,282

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold.

Property, Plant and Equipment, net – Our property and equipment are recorded at cost. Assets held under capital leases are capitalized at the commencement of the lease at the lower of the present value of minimum lease payments at the inception of the lease or fair value. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over estimated useful lives of four to seven years, and amortization is computed using the straight-line method over the life of the applicable lease. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from our accounts and any resulting gain or loss is reflected in our consolidated statements of operations.

Land Improvements – Our land improvements are recorded at cost provided by our property association. These costs will continue to be capitalized until construction has been completed. Land improvements will not be depreciated ~~after~~until the construction has been completed by the property association.

Long-Lived Assets Impairment Assessment – Our long-lived assets are subject to an impairment test if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying value of intangibles or other long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, we use the projected undiscounted cash flow method or realizable value to determine whether an impairment exists, and then measure the impairment using discounted cash flows.

Revenue Recognition – The Company derives revenues from the sale of product in accordance to ASC Topic 606. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services.

Revenue is recognized based on the following five step model:

	-	Identification of the contract with a customer
	-	Identification of the performance obligations in the contract
	-	Determination of the transaction price
	-	Allocation of the transaction price to the performance obligations in the contract
	-	Recognition of revenue when, or as, the Company satisfies a performance obligation

Performance Obligations – Sales of products are recognized when all the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The Company uses an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus margin approach when one is not available. Historically the Company’s contracts have not had multiple performance obligations. The large majority of the Company’s performance obligations are recognized at a point in time related to the sale of products.

Cost of Goods Sold – Our cost of goods sold includes the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labelling of cannabis products; personnel-related costs, fees for third-party services, such as testing and transportation costs related to our distribution services.

Basic and Diluted Net Income Per Share – Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share assumes that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

	March 31, 2022			December 31, 2021
	June 30, 2022			December 31, 2021
Numerator:
Net income attributable to common shareholders	$	(~~484~~1,~~255~~849,495	)		(5,504,670	)
Denominator:
Weighted-average number of common shares outstanding during the period		~~560~~561,~~910~~807,~~403~~925			515,339,023
Dilutive effect of stock options, warrants, and convertible promissory notes		-			-
Common stock and common stock equivalents used for diluted earnings per share	$	(0.00	)	$	(0.01	)

Derivative Financial Instruments - The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund its business needs, including convertible notes and warrants and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with warrants to purchase common stock and convertible notes.

Fair Value of Financial Instruments – We value our financial assets and liabilities using fair value measurements. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

Level 2: Observable inputs other than prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated with observable market data.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.

The carrying amount of our cash and cash equivalents approximates fair value because of the short-term nature of the instruments. The carrying amount of our notes payable at December 31, 2019, approximates their fair values based on comparable borrowing rates available to the company.

There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the ~~three~~six months ended ~~March~~June 3130, 2022 and year ended December 31, 2021.

SUMMARY OF DERIVATIVE LIABILITIES

	~~Level 1~~	Level 1		~~Level 2~~	Level 2		~~Level 3~~	Level 3		~~Total~~	Total
Derivative Liabilities March 31, 2022	$	-		$	-		$	9,960		$	9,960
Derivative Liabilities June 30, 2022		$	-		$	-		$	3,498		$	3,498
Derivative Liabilities December 31, 2021	$	-$	-	$	-$	-	$	~~127,392~~$	127,392	$	~~127,392~~$	127,392
Derivative Liabilities	$	-$	-	$	-$	-	$	~~127,392~~$	127,392	$	~~127,392~~$	127,392

Items measured at fair value on a non-recurring basis

The Company’s prepaids and other current assets, long lived assets, including property and equipment, and goodwill are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Income Taxes – Income tax assets and liabilities are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as net operating loss and tax credit carryovers. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized, or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

We follow the provisions of ASC 740, Income Taxes. Because of ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740.

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

We have created our tax provision leveraging known tax court cases involving various marijuana dispensaries and other cannabis related businesses, including the section of the IRS Tax code of 280E. The U.S. Tax Code Section 280E is the federal statute that states that a business engaging in the trafficking of a Schedule I or II controlled substance, which includes cannabis and cannabis related products, are barred from taking the tax deductions or credits in their federal tax returns which are not considered as part of the business’ cost of goods sold. Given the guidance offered by the Tax code 280E we have prepared our tax provision according to this tax code.

Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.

On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no significant impact on our income taxes for the ~~three~~six months ended ~~March~~June 3130, 2022 and 2021, respectively.

Research and Development Expenses – Research and development (“R&D”) costs are charged to expense as incurred. Our R&D expenses include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

General and Administrative Expenses – General and administrative expenses consist primarily of personnel-related costs, fees for professional and consulting services, travel costs, rent, bad debt expense, general corporate costs, and other costs of administration such as human resources, finance and administrative roles.

Commitments and Contingencies – Certain conditions may exist as of the date our financial statements are issued, which may result in a loss, but which will only be resolved when one or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Net Loss Per Share – We compute net loss per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net loss per share includes no dilution and is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic net loss per share) and potentially dilutive securities that are not anti-dilutive.

Cash and Cash Equivalents – The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash equivalents may be invested in money market funds, certificates of deposit or other interest-bearing accounts.

Concentration of Credit Risk – Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.

13Accounts Receivable and Revenue – The accounts receivable balance was $762 as of June 30, 2022 and $278,422 as of December 31, 2021. As of June 30, 2022, 100% of accounts receivable consisted of one customer and the remaining accounts receivable was determined to be uncollectible. During the three months ended June 30, 2022, 73% of the sales came from Summit Boys product third party sellers, 15% came from online sales, and the remainder of the sales was distributed between all other customers. During the three months ended June 30, 2021, we diversified our customer base, but still have 30% of the revenues from one customer.

~~Accounts~~We ~~Receivable~~periodically ~~and~~review ~~Revenue~~the –value ~~The~~of our accounts receivable ~~balance~~and ~~was~~provide ~~$278,356~~an asallowance offor ~~March~~doubtful ~~31,~~accounts ~~2022~~based ~~and~~on ~~$278,422~~our asassessment of ~~December~~ ~~31,~~the ~~2021.~~age As of ~~March~~the ~~31,~~receivable ~~2022~~ and ~~December~~its ~~31, 2021, 82% of accounts receivable consisted of four customers~~collectability. During the three months ended ~~March~~June 3130, 2022, ~~one~~the ~~customer~~Company ~~had~~reviewed ~~11% of~~ the ~~sales~~accounts receivable and ~~41%~~based ofon the ~~sales~~aging ~~came~~and ~~from~~likelihood ~~online~~of ~~CBD~~collectability, ~~HourGlass~~an ~~sales.~~allowance ~~During~~for ~~the~~doubtful ~~three~~accounts ~~months ended~~was ~~March~~created ~~31,~~in ~~2021,~~the weamount ~~diversified our customer base~~of $250,054. Any ~~but~~allowance ~~still~~is ~~have~~charged ~~30%~~to ofgeneral ~~the~~and ~~revenues~~administrative ~~from one customer~~expenses.

Recently Issued Accounting Pronouncements – From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update (“ASU”). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our condensed consolidated financial statements upon adoption.

Recently Issued Accounting Pronouncements Not Yet Adopted

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326) (“ASU No. 2022-02”). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

Recently Issued Accounting Pronouncements Adopted

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

NOTE 3 – GOING CONCERN

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the ~~three~~six months ended ~~March~~June 3130, 2022, we we incurred a net loss of $~~484~~1,~~255~~849, 495, had a working capital deficit of $76,~~395~~876,~~991~~ 837 and had an accumulated deficit of $1718,~~310~~675,~~419~~ 659 at ~~March 31~~June 30, 2022. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements

Management’s plan regarding this matter is to, amongst other things, seek additional equity financing by selling our equity securities and obtaining funds through the issuance of debt. We cannot be certain that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders may be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences and/or privileges senior to those of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affected if we are unable to raise additional capital or operate profitably.

NOTE 4 – RIGHT OF USE ASSET AND LIABILITY

We lease capital equipment in a suitable, compliant cannabis facility located in the city of Desert Hot Springs. In addition, we entered into this operating land lease agreement with Coachillin’ Holdings LLC on September 1, 2018 to rent approximately 2,268 square feet of leasable land area. The operating lease renews annually and has a base rent of $0.50 square foot of leasable area of the designated premise assigned by Coachillin’ Holdings LLC. We paid an initial non-refundable prepaid rent of $3,402 which was expensed during the three months following the signed agreement, and we will continue to pay $1,134 monthly.

The Company entered into a 36-month lease agreement for office space in July 2019 at $6,963 a month, with an approximate 2% increase annually.

The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 6-10% to estimate the present value of the right of use liability.

The Company has right-of-use assets of $5115,~~299~~928, right-of-use liability of $5215,~~147~~928 as of ~~March~~June 3130, 2022. Operating lease expense for the ~~three~~ six months ended ~~March~~June 3130, 2022 was $24,932.

The following table provides the maturities of lease liabilities at ~~March~~June 3130, 2022:

Maturity of Lease Liabilities
2022		326,~~584~~804
2023		1310,~~608~~206
2024		~~10,206~~-
2025		-
2026		-
2027 and thereafter		-
Total future undiscounted lease payments		5617,~~398~~010
Less: Interest		(41,~~251~~082	)
Present value of lease liabilities	$	5215,~~147~~928

NOTE 5 – INVENTORY

At ~~March~~June 3130, 2022 and December 31, 2021, our inventory was, as follows:

SCHEDULE OF INVENTORY

	March 31, 2022		December 31, 2021
	June 30, 2022		December 31, 2021
Raw material	$	~~298~~85,~~722~~294	$	~~304~~84,~~331~~951
Work in process		-20,000		-
Finished goods		84234,~~517~~018		84304,~~951~~331
Total inventory	$	~~383~~339,~~239~~312	$	389,282

At ~~March~~June 3130, 2022 and December 31, 2021, finished goods included $~~16,763~~690 and $20,904 on consignment, respectively. In addition, some finished goods product needed to be reworked and is temporarily moved to work in process.

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,941 reduction in inventory. Most of the product was salvageable and will be ready for resale in August 2022.

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net of accumulated depreciation and amortization, at ~~March~~June 3130, 2022 and December 31, 2021 was as follows:

	March 31, 2022			December 31, 2021
	June 30, 2022			December 31, 2021
Vehicle	$	41,142		$	41,142
Furniture and equipment		7,494			7,494
Extraction equipment		302,636			302,636
Extraction laboratory		126,707			126,707
Warehouse facility		50,158			50,158
Land and land improvement/development		1,505,~~011~~012			1,505,~~011~~012
Accumulated depreciation and amortization		(~~287~~307,~~216~~888	)		(263,522	)
Property, plant and equipment	$	1,745,932		$	1,769,627
Property, plant, and equipment	$	1,725,261		$	1,769,627

The Company acquired the extraction equipment, laboratory, and warehouse facility during 2018 and 2019 and prepared and final testing for future production. Final preparations for certain extraction and warehouse work were completed, and these related assets were placed in service on April 1, 2019, at which time we commenced depreciating this asset.

The amount of related depreciation expense for the ~~three~~six months ended ~~March~~June 3130, 2022 and 2021 is $2344,~~695~~366 and $2246,~~629~~113, respectively.

NOTE 7 – CAPITAL LEASE PAYABLE

Capital lease payable consists of a capital lease agreement entered into in April 2018 to finance the purchase of various lab and manufacturing equipment. The outstanding balance on the 48-month installment capital lease was $0 and $8,822 as of ~~March~~June 3130, 2022 and December 31, 2021, respectively. The terms of the 48-month capital lease specify monthly payments of $4,575. The interest rate implicit in the lease is is about 15% and the maturity date was February 2022. The lease has been paid in full. and we now retain ownership of the equipment

In addition, the Company entered into additional 48-month leases in May 2019 for production facilities and storage of product. Monthly payments for the facility and storage totals $1,935.

A summary of minimum lease payments on capital lease payable for future years is as follows:

	March 31, 2022
	June 30, 2022
Remainder 2022	$	1711,~~415~~610
2023		7,740
2024		-
2025		-
2026		-
Thereafter		-
Total minimum lease payments		2519,~~155~~350
Less: amount representing interest		(~~636~~386	)
Capital lease liability	$	2418,~~519~~964

NOTE 8 – NOTES PAYABLE

In October 2017, in connection with our purchase of two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park, the Company issued a first and second trust deed note in the amounts of $700,000 and $200,000, respectively. The first and second trust deed notes are long-term notes and are interest only notes, at 13.0%, and mature in August 2022, with the full principal payment due at maturity. For the $700,000 loan, the monthly interest payment is approximately $7,500. For the $200,000 loan, the monthly interest payment is approximately $2,200. Unpaid interest as of ~~March~~June 3130, 2022 is $37,888 and $6,495, for the two loans respectively. The 1st and 2nd trust deeds are secured by the land as well as property owned by two officers of the company and three other related parties. Also, each party has personally guaranteed or pledged additional collateral. The notes include a debt discount as of ~~March~~June 3130, 2022 of $9,000. The Company plans to repay these notes with the proceeds from the recapitalization disclosed in the “Binding Letter of Intent to Acquire Diagnostic Lab Corporation” in “Grapefruit’s Business Development” in Note 1.

In April 2018, the Company issued a note due 60 days after funding to an unrelated third party with a principal amount of $250,000 and immediate interest charge totalling $125,000. As of March 31, 2022, the note has not been repaid and was amended to carry an additional 10% interest rate of the total balance due. Accrued interest for this loan totals $265,625. The note is past due. Two officers of the Company have personally guaranteed the loan.17

In ~~March~~April ~~2022~~2018, the Company issued ~~another~~a note ofdue ~~$40,000~~ 60 days after funding to an unrelated third party with ~~10%~~a principal amount of $250,000 and immediate interest charge totaling $125,000. ~~which~~As ~~will~~of ~~mature~~June in30, 62022, ~~months.~~the note has not been repaid and was amended to carry an additional 10% interest ~~The~~rate ~~unrelated~~of ~~party~~the ~~has~~total ~~notes~~balance ~~totalling~~due. Accrued interest for this loan totals $46265,~~000,~~625. The note is past due. Two officers of the Company have ~~both~~personally ~~with~~guaranteed ~~similar~~the ~~terms~~loan.

In March and May 2022, the Company issued another note of $40,000 and $10,000, respectively, to an unrelated party with 10% interest, which will mature in 6 months. In October 2021, there was an additional note for $6,000. The unrelated party has notes totaling $56,000, all with similar terms.

NOTE 9 – CONVERTIBLE NOTES PAYABLE

Amortization of note discounts, which is included in interest expense, amounted to $~~145~~235,~~333~~046 during the ~~three~~six months ended ~~March~~June 3130, 2022 and $~~234~~509,~~527~~817 for the ~~three~~six months ended ~~March~~June 3130, 2021.

Grapefruit acquired convertible notes in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) On May 31, 2019, the Company ~~executed~~ executed the SPA with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby we are obligated to file a registration statement to register the resale of the shares underlying the Securities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement. ~~Pursuant~~ Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the SPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the day IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of $1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing were completed. The Company has received gross proceeds of $4,052,750. The Notes have a two-year term and will bear interest at 10%, with a default interest rate of 24%. As of June 30, 2022, two notes are in default.

On April 15, 2021, the company renegotiated the debt agreement related to these notes modifying the convertible notes conversion price from a variable rate to a fixed rate conversion price of $0.075 per share with an effective date of December 31, 2021. As a result of the agreement, the Company recorded a noncash expense for the change in the value of derivative instruments of $40,372,883, which was simultaneously offset by a noncash gain of $39,640,477 from the extinguishment of debt, resulting a net loss of $732,406 from the renegotiation of the debt.

On February 26, 2021, the company issued a convertible note for $450,000. The note has an interest rate of 10% and matures in 12 months. Note is currently in default with no updated maturity date. The note continues to accrue interest, which has an accrued interest balance of $58,822 as of ~~March~~June 3130, 2022. This note was included in the amendment making it convertible at $0.075 per share.

17On June 22, 2022, Auctus converted $1,200,000 of convertible notes and $545,818 of accrued interest at the fixed rate of $0.075 for 23,277,573 shares.

In addition, the Company has eleven other convertible notes comprising $296,000 outstanding and they are currently in default. The interest on these notes varies from 5-10%. We are in the process of converting eight of the notes amounting to $241,000.

SCHEDULE OF CONVERTIBLE NOTES

December 31, 2021 Balance	$	3,966,048
Additional notes		-
Note conversions/repayment		(1,200,000	)
Note discount		(90,043	)
June 30, 2022 Balance	$	2,676,005

NOTE 10 – NOTES PAYABLE, RELATED PARTY NOTES PAYABLES, AND OPERATING LEASE – RELATED PARTY

Notes payable to officers and directors as of ~~March~~June 3130, 2022 and December 31, 2021 are due on demand and consisted of the following:

	March 31, 2022		December 31, 2021
	June 30, 2022		December 31, 2021
Payable to an officer and director	$	~~680~~858,~~663~~788	$	528,404
Payable to an individual affiliate of an officer and director		~~149~~238,~~740~~000		47,560
Payable to a company affiliate to an officer and director		~~162~~169,~~198~~038		126,617
Notes payable to officers and directors	$	~~992~~1,~~601~~265,826	$	702,581

Notes payables bear interest at 10%.

A related party leased two eco-pods in April 2019 and May 2019, which are refurbished shipping containers, located on this specific parcel within Coachillin’. The lease is treated as an operating lease and payment responsibility is ultimately the responsibility of the related party. The Company assumed these lease payment obligations in May 2019. The monthly payments are $1,055 and $880, for the duration of the lease terms of four and five years, respectively.

On May 17, 2021, related parties converted $699,236 of principal and accrued interest, a total of 11,710,465 shares of common stock.

NOTE 11 – EQUITY

Preferred Stock

The Company has authorized 1,000,000 shares of $0.0001 par value preferred stock. As of ~~March~~June 3130, 2022, and December 31, 2021, there are no no shares of preferred stock outstanding.

Common Stock

The Company is authorized to issue 1,000,000,000 shares of $0.0001 par value common stock.

During the ~~three~~six months ended ~~March~~June 3130, 2022 the Company issued a total of 242,527,000 shares for services rendered valued at $~~729~~57,809; 2,325,878 shares were issued related to legal settlement valued at $1135,~~665~~127; 23,277,573 shares were issued for the conversion of notes and accrued interest.

During the ~~three~~six months ended ~~March~~June 3130, 2021 the Company issued a total of 16,~~399~~349,937 shares ~~were issued~~ for services rendered valued at $55250,~~944~~064; 1 20,~~666~~114,~~667~~651 shares were issued related to ~~for~~legal asettlement and debt settlement with related parties valued at $2,281,695; 13,352,264 shares were issued related to the conversion of convertible notes valued at $51996,~~667~~620; 1,000,000 shares were issued for a stock purchase valued at $0.075 per share; and 2,000,000 shares were issued for warrant exercised at $0.125 per share.

As of ~~March~~June 3130, 2022, there were approximately 610 record holders of our common stock, not including shares held in “street name” in brokerage accounts the number of which is unknown. As of ~~March~~June 3130, 2022, there were 559,~~512~~506,622 shares of our common stock outstanding on record.

Stock Option Plan

During 2014, the Board of Directors adopted, and the shareholders approved, the 2014 Stock Option Plan under which a total of 1,811,401 shares of common stock had been reserved for issuance. The 2014 Stock Option Plan will terminate in September 2024.

Stock Options

As of ~~March~~June 3130, 2022, employees of the Company hold options to purchase 250,000 shares of common stock granted in 2016 at an exercise price of $1.00. On March 28, 2021, the Company granted a board member an option to purchase 750,000 shares of common stock at $0.025. There are six month vesting periods for a block of 250,000 shares starting October 1, 2021.

SCHEDULE OF STOCK OPTIONS ACTIVITY

Transactions in FY 2022	Quantity		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Life
Outstanding, December 31, 2021		250,000	$	1.00		3.3207
Granted		750,000	$	0.025		54.0176
Exercised		-
Cancelled/Forfeited		-
Outstanding, March 31, 2022		1,000,000	$	0.27		4.59
Outstanding, June 30, 2022		1,000,000	$	0.27		4.34
Exercisable, March 31, 2022		500,000	$	0.51		3.91
Exercisable, June 30, 2022		750,000	$	0.35		4.03

The weighted average remaining contractual life of options outstanding issued under the agreements was 4.5934 years at ~~March~~June 3130, 2022.

NOTE 12 — WARRANTS

Following is a summary of warrants outstanding at ~~March~~June 3130, 2022:

SUMMARY OF WARRANTS OUTSTANDING

Number of Warrants		~~Exercise Price~~		Exercise Price		~~Expiration Date~~	Expiration Date
37,500			0.10			Apr-22
	500,000				0.10		Aug-22
2,800,000			0.40			May-22
	575,000				0.10		Apr-23
500,000			0.10			Aug-22
	125,000				0.10		May-23
575,000			0.10			Apr-23
	162,500				0.10		Aug-23
125,000			0.10			May-23
	302,776				0.10		Jan-24
162,500			0.10			Aug-23
	14,000,000				0.125		May-24
302,776			0.10			Jan-24
	15,000,000				0.15		May-24
14,000,000			0.125			May-24
	8,000,000				0.25		May-24
15,000,000			0.15			May-24
	20,000,000				0.075		Apr-26
8,000,000			0.25			May-24
	2,250,000				0.20		Feb-26
20,000,000			0.075			Apr-26
2,250,000			0.20			Feb-26

Grapefruit recorded warrants to issue common stock upon exercise in its acquisition of Imaging3, Inc. on July 10, 2019. ~~(See Note 15.)~~ As part of the SEA, the Company also issued 16,000,000 warrants to purchase 16,000,000 shares of the Company’s common stock at an exercise price of $0.125 per share, 15,000,000 warrants to purchase 15,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, 8,000,000 warrants to purchase 8,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share for a period of two year from the date of issuance. (See Note 9)

In addition to the Notes in connection with the SPA agreement, GPFT issued to the Investor a warrant to purchase 16,000,000 shares of its common stock at $0.125 per share, a warrant to purchase 15,000,000 shares at $0.15 per share and a warrant to purchase 8,000,000 shares at $0.25 per share (collectively, the “Warrants”). The Warrants are “cash only” and are callable if GPFT stock trades on the OTCQB at 200% or more of the given exercise price for 5 consecutive days.

On February 26, 2021, 2,250,000 warrants were issue with an exercise price of $0.125 in relation to the convertible note (See Note 9 Convertible note payable). On April 15, 2021 as part of the renegotiated terms of the convertible notes, 20,000,000 additional warrants were issued at an exercise price of $0.075.

NOTE 13 — DERIVATIVE LIABILITIES

Grapefruit recorded derivative instruments in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) The Company’s only asset or liability measured at fair value on a recurring basis was its derivative liability associated with related warrants to purchase common stock and the conversion features embedded in convertible promissory notes.

In connection with financing transactions, the Company issued warrants to purchase common stock and convertible promissory notes. These instruments included provisions that could result in a reduced exercise price based on specified full-ratchet anti-dilution provisions. The “reset” provisions were triggered in the event the Company subsequently issued common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than contractually specified amounts. Upon triggering the “reset” provisions, the exercise / conversion price of the instrument will be reduced. Accordingly, pursuant to ASC 815, these instruments were not considered to be solely indexed to the Company’s own stock and were not afforded equity treatment.

On April 15, 2021, the company renegotiated conversion terms on $4,502,750 of convertible notes with Auctus. All variable conversion prices were replaced with a fixed conversion price of $0.075. In addition, the Company issued an additional 20,000,000 warrants with an exercise price of $0.075 per share.

The following table summarizes activity in the Company’s derivative liability during the ~~three~~six-month month period ended ~~March~~June 3130, 2022:

SUMMARY OF DERIVATIVE LIABILITY

12-31-21 Balance	$	127,392
December 31, 2021 Balance	$	127,392
Creation/acquisition		-
Reclassification of equity		-
Change in Value		(~~117~~123,~~432~~894	)
3-31-22 Balance	$	9,960
June 30, 2022 Balance	$	3,498

The Company classifies the fair value of these derivative liabilities under level 3 of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Binomial Tree model. The Company’s stock price and estimates of volatility are the most sensitive inputs in validation of assets and liabilities at fair value. The liabilities were measured using the following assumptions:

SCHEDULE OF ASSUMPTIONS USED

Term	1-2 years
Dividend Yield	0	%
Risk-free rate	1.1772% - 12.6380	%
Volatility	~~162~~167	%

NOTE 14 – ~~INVESTMENTS~~SEGMENT INFORMATION

Segment reporting is prepared on the same basis that the Company’s Chief Executive Officer, who is the Company’s Chief Operating Decision Maker, manages the business, makes operating decisions and assesses performance.

As of June 30, 2022 the Company’s four segments are as follows:

Segment		Description
Retail		The retail segment includes products sold through our online stores and third-party sales teams.
Wholesale		The wholesale segment includes products sold to our preexisting and newly acquired customers.

The majority of costs are run through the wholesale segment, which includes the fixed costs associated with production of inventory. The Company has begun to promote sales of Summit Boys branded product, which is primarily sold direct to consumer, and felt is necessary to differentiate between the two segments. Segment information is summarized below:

SCHEDULE OF SEGMENT INFORMATION


	Three months ended			Three months ended			Six months ended			Six months ended
	June 30, 2022			June 30, 2021			June 30, 2022			June 30, 2021
Revenue
Retail	$	22,707		$	4,132		$	25,056		$	4,132
Wholesale		1,355			78,356			4,655			429,172
Revenue	$	24,062		$	82,488		$	29,711		$	433,304

Gross margin
Retail	$	(728	)	$	1,835		$	149		$	2,505
Wholesale		(145,691	)		(77,531	)		(213,346	)		(154,416	)
Gross margin	$	(146,419	)	$	(75,696	)	$	(213,197	)	$	(151,911	)

NOTE 15 – INVESTMENTS

Investment in Hemp

In September 2019, the Company invested in hemp product that was purchased and stored by a third party. The Company expects to sell the product by the beginning of next year. Due to the increased harvests, the salability of the product decreased, necessitating the complete mark down, which occurred in 2021.

NOTE 1516 – COMMITMENTS AND CONTINGENCIES

Mentor Group, Inc. vs Imaging3, Inc. Settlement

On March 8, 2022, Grapefruit USA, Inc. was contacted by an attorney about outstanding litigation between Mentor Group, Inc. and Imagaing3, Inc. The settlement was for $27,593 of past debt, $8,869 in attorney fees, and $3,644 of interest. Currently no payment plan is in place. This debt is related Imaging3, Inc.’s prior business activities which preceded Grapefruit’s acquisition of Imaging3, Inc., and was inherited or assumed by Grapefruit.

Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP vs Imaging3, Inc. Settlement

The Company came to a settlement with Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP (“Galileo”) for $75,572 with an interest rate of 10%, requiring payments of $7,300 per month beginning in August 2021 until paid in full. This debt is related Imaging3, Inc.’s prior business activities which preceded Grapefruit’s acquisition of Imaging3, Inc., and was ‘inherited’ or ‘assumed’ by Grapefruit.

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLP

The Company came to a settlement agreement with Greenberg Glusker Fields Claman & Machtinger LLP (“Greenberg”). Three $68,000 payments are to be made in relation to the timing of the three latter tranches mentioned in “Auctus Financing” or before November 30, 2019. As of now, $68,000 has been paid; late penalties are currently being assessed. In addition, 7,628,567 shares are to be issued as part of the settlement agreement—7,213,933 of the shares were issued as of ~~March~~June 3130, 2022. In May 2021, the Company issued 3,920,865 shares as part of the make-whole clause in the agreement. On October 26, 2021, the Company issued 600,000 shares as part of the make-whole clause in the agreement. Additional shares may need to be issued in the future. This debt is related Imaging3, Inc.’s prior financing activities which preceded Grapefruit’s acquisition of Imaging3, Inc., and was ‘inherited’ or ‘assumed’ by Grapefruit.

NOTE 1617 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10Q and determined that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements.

2022

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statements

This Form 10-Q contains financial projections and other “forward-looking statements,” as that term is used in federal securities laws, about Grapefruit’s financial condition, results of operations and business. These statements include, among others, statements concerning the potential for revenues and expenses and other matters that are not historical facts. These statements may be made expressly in this Form 10-K. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions used in this Form 10-K. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied by us in those statements. The most important facts that could prevent us from achieving our stated goals include, but are not limited to, the following:

	(a)	volatility or decline of our stock price;

	(b)	potential fluctuation in quarterly results;

	(c)	our failure to earn revenues or profits;

	(d)	inadequate capital to continue the business and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;

	(e)	failure to make sales;

	(f)	changes in demand for our products and services;

	(g)	rapid and significant changes in markets;

	(h)	litigation with or legal claims and allegations by outside parties, causing us to incur substantial losses and expenses;

	(i)	insufficient revenues to cover operating costs;

	(j)	dilution in the ownership of the Company through the issuance by us of additional securities and the conversion of outstanding warrants, notes and other securities;

We cannot assure that we will be profitable. We may not be able to develop, manage or market our products and services successfully. We may not be able to attract or retain qualified executives and technology personnel. We may not be able to obtain customers for our products or services. Our products and services may become obsolete. Government regulation may hinder our business. Additional dilution in outstanding stock ownership will be incurred due to the issuance or exercise of more shares, warrants and other convertible securities.

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. We caution you not to place undue reliance on the statements, which speak only as of the date of this Form 10-Q. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may make. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

The following discussion should be read in conjunction with our financial statements and notes to those statements. In addition to historical information, the following discussion and other parts of this annual report contain forward-looking information that involves risks and uncertainties.

Results of Operations for the Three Months Ended March 31, 2022 as compared to the Three Months Ended March 31, 2021.

	Three months ended			Three months ended
	March 31, 2022			March 31, 2021
Net revenues	$	5,650		$	350,815
Cost of goods sold		71,861			423,435
Gross income (loss)		(66,211	)		(72,620	)
Sales expense		566			3,596
Stock based compensation		-			-
Stock option expenses		14,990			-
General and administrative expense		223,984			401,412
Loss from operations		(305,751	)		(477,628	)
Change in value of derivatives		117,432			(59,319	)
Interest and other income (expense)		(295,936	)		(879,754	)
Net loss before income taxes		(484,255	)		(1,416,701	)
Tax provision		-			-
Net loss		(484,255	)		(1,416,701	)
Loss attributable to noncontrolling interest		-			-
Net loss attributable to Grapefruit USA, Inc.	$	(484,255	)	$	(1,416,701	)

The following sets forth selected items from our statements of operations for three months ended March 31, 2022 and for the three months ended March 31, 2021.

Revenue for the three months ended March 31, 2022 was $5,650 compared to $350,815 for the corresponding period in 2021, a decrease of $345,165 or 98.4%. The decrease was primarily due to the decline of our distribution business caused by a combination of decreased demand for and an over-supply of cannabis flowers in California. As a result of these market forces beyond our control we have severely limited our distribution operations and commenced the process of transitioning into a canna-biotech firm focusing on further developing and marketing of cannabis products based on our patented Hourglass Technology. We have received approval of our NNCP from Health Canada which authorizes us to manufacture and sell our Hourglass™ products throughout Canada.

Cost of goods sold for the three months ended March 31, 2022 was $71,861 as compared to $423,435 for the corresponding period in 2021, a decrease of $351,574, or 83.0%. Included in cost of goods sold are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels.

Our resulting gross loss for the three months ended March 31, 2022 was $66,211 as compared with the gross loss of $72,620 for the corresponding period in 2021, a decrease of $6,409, or 8.8%. The decrease was a result of the general decrease in sales and the associated costs of good sold.

Sales expense for the three months ended March 31, 2022 was $566 compared to the $3,596 for 2021, a decrease of $3,030. The decrease was a result of a decrease in sales. Stock option expenses for the three months ended March 31, 2022 were $14,990 compared to $0 for 2021, an increase of $14,990. General and administrative expenses for the three months ended March 31, 2022 were $223,984 compared to $401,412 for 2021, a decrease of $177,428, or 44.2%.

Our resulting net loss from operations for the three months ended March 31, 2022 was $305,751 as compared to $477,628 for the corresponding period for 2021, a decrease of $171,877, or 36%. Change in value of derivatives gain for the three months ended March 31, 2022 was $117,432 as compared to the loss of $59,319 for 2021, an increase of $176,751, or 298.0%.

In August 2021, Grapefruit acquired a majority of Summit Boys, a non-operating, intellectual property subsidiary with minimal to no expenses. There was no activity for the three months ended March 31, 2022. Due to the fact that there was minimal to no activity, management deemed it unwarranted to provide separate financials for the subsidiary.

Our resulting net loss attributable to Grapefruit USA, Inc. and subsidiary for the three months ended March 31, 2022 was $484,255 as compared to $1,416,701 for the corresponding period for 2021, a decrease of $932,446, or 65.8%.

COVID-19 Impact

During the three months ended March 31, 2022, the company experienced severe restrictions on consumers and the retail locations at which consumers purchase our products. Whereas during the three months ended March 31, 2021, the company still had the same consumer restrictions, but we were able to continue the flower distribution with the remaining inventory, which accounts for out revenues in the first quarter of 2021. As a result of these restrictions, we believe demand for our products was subdued during the period. During the comparable three months in 2021, and as a result of the COVID-19 pandemic, we saw an increase in demand for our cannabis products driven by consumer pantry-loading and increased consumption of our products due to concerns about future availability of products and or concerns about whether retail locations that sell our products would remain open. Despite the COVID-19 pandemic, have continued to introduce new products in the market.

The full extent to which COVID-19 may impact our business, including our operations and the market for our securities and our financial condition, will depend on future developments, which are highly uncertain and cannot be predicted at this time. These include the duration, severity and scope of the pandemic, the development and availability of effective treatments and vaccines, and further action taken by the government and other third parties in response to the pandemic. In particular, COVID-19 and government efforts to curtail COVID-19 could impede our production facilities, increase operating expenses, result in loss of sales, affect our supply chains, impact performance of contractual obligations and require additional expenditures to be incurred.

Liquidity and Capital Resources

Our cash position decreased to $5,153 as of March 31, 2022 from $9,095 as of December 31, 2021. Our total current assets decreased to $700,977 as of March 31, 2021, from $714,199 as of December 31, 2021.

Our total current liabilities increased to $8,096,968 as of March 31, 2022 from $7,703,573 as of December 31, 2021.

~~During~~Results ~~the three months ended March 31, 2022, we used $257,366~~ of ~~net~~Operations ~~cash~~ for ~~operating activities, as compared to cash used by operations of $261,031 used during~~ the ~~three~~Three ~~months~~Months ~~ended~~Ended ~~March~~June ~~31, 2021. Net cash used in investing activities during the three months ended March 31, 2022 was $0, as compared to $~~30,~~521~~ ~~during the three months ended March 31, 2021. Net cash provided by financing activities during the three months ended March 31,~~ 2022 ~~was $253,424,~~ as compared to ~~$432,647 during~~ the ~~three~~Three ~~months~~Months ~~ended~~Ended ~~March~~June 3130, 2021.

	Three months ended			Three months ended
	June 30, 2022			June 30, 2021
Net revenues	$	24,062		$	82,488
Cost of goods sold		162,450			157,163
Gross income (loss)		(138,388	)		(74,675	)

Stock based compensation		195,682			221,620
Stock option expenses		6,008			32,877
General and administrative expense		526,286			273,112
Loss from operations		(866,364	)		(602,284	)
Change in value of derivatives		6,462			136,652
Interest and other income (expense)		(505,338	)		(880,994	)
Net loss before income taxes		(1,365,240	)		(1,346,626	)
Tax provision		-			-
Net loss		(1,365,240	)		(1,346,626	)
Loss attributable to noncontrolling interest		-			-
Net loss attributable to Grapefruit USA, Inc.	$	(1,365,240	)	$	(1,346,626	)

The following sets forth selected items from our statements of operations for three months ended June 30, 2022 and for the three months ended June 30, 2021.

Revenue for the three months ended June 30, 2022 was $24,065 compared to $82,488 for the corresponding period in 2021, a decrease of $58,426 or 70.8%. The decrease was primarily due to the decline of our distribution business caused by a combination of decreased demand for and an over-supply of cannabis flowers in California. As a result of these market forces beyond our control we have severely limited our distribution operations and commenced the process of transitioning into a canna-biotech firm focusing on further developing and marketing of cannabis products based on our patented Hourglass Technology. On March 21, 2022, we received approval of our NNCP from Health Canada (NNCP ID No. NP-V2EHUWO907) which authorizes us to manufacture and sell our Hourglass™ products throughout Canada.

Cost of goods sold for the three months ended June 30, 2022 was $162,450 as compared to $157,163 for the corresponding period in 2021, a decrease of $5,287, or 3.4%. Included in cost of goods sold are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,500 reduction in inventory. Most of the product was salvageable and will be ready for resale in August 2022.

Our resulting gross loss for the three months ended June 30, 2022 was $138,388 as compared with the gross loss of $74,675 for the corresponding period in 2021, a decrease of $63,713, or 85.3%. The decrease was a result of the general decrease in sales and the associated costs of goods sold.

Stock based compensation for the three months ended June 30, 2022 were $195,682 compared to $221,620 for 2021, decrease of $25,938, or 11.7%. Stock option expenses for the three months ended June 30, 2022 were $6,008 compared to $32,877 for 2021, a decrease of $26,869. General and administrative expenses for the three months ended June 30, 2022 were $526,286 compared to $274,748 for 2021, an increase of $251,538, or 91.6%. This increase was due to the evaluation of the collectability of our accounts receivable. Based on the aging and likelihood of collectability, an allowance for doubtful accounts was created in the amount of $257,594.

Our resulting net loss from operations for the three months ended June 30, 2022 was $866,364 as compared to $602,284 for the corresponding period for 2021, an increase of $264,080, or 43.8%. Change in value of derivatives gain for the three months ended June 30, 2022 was $6,462 as compared to $136,652 for 2021, a decrease of $375,656, or 42.6%.

Our resulting net loss attributable to Grapefruit USA, Inc. and subsidiary for the three months ended June 30, 2022 was $1,365,240 as compared to $1,346,626 for the corresponding period for 2021, a decrease of $18,614, or 1.4%.

Results of Operations for the Six Months Ended June 30, 2022 as compared to the Six Months Ended June 30, 2021.

	Six months ended			Six months ended
	June 30, 2022			June 30, 2021
Net revenues	$	29,711		$	433,304
Cost of goods sold		234,311			580,598
Gross income (loss)		(204,600	)		(147,294	)
Sales expense		-			1,960
Stock based compensation		195,905			239,044
Stock option expenses		20,998			32,877
General and administrative expense		750,612			658,737
Loss from operations		(1,172,115	)		(1,079,912	)
Change in value of derivatives		123,894			77,333
Interest and other income (expense)		(801,274	)		(1,760,748	)
Net loss before income taxes		(1,849,495	)		(2,763,327	)
Tax provision		-			-
Net loss		(1,849,495	)		(2,763,327	)
Loss attributable to noncontrolling interest		-			-
Net loss attributable to Grapefruit USA, Inc.	$	(1,849,495	)	$	(2,763,327	)

The following sets forth selected items from our statements of operations for six months ended June 30, 2022 and for the six months ended June 30, 2021.

Revenue for the six months ended June 30, 2022 was $29,711 compared to $433,304 for the corresponding period in 2021, a decrease of $403,593 or 93.1%. The decrease was primarily due to the decline of our distribution business caused by a combination of decreased demand for and an over-supply of cannabis flowers in California. As a result of these market forces beyond our control we have severely limited our distribution operations and commenced the process of transitioning into a canna-biotech firm focusing on further developing and marketing of cannabis products based on our patented Hourglass Technology. On March 21, 2022, we received approval of our NNCP from Health Canada (NNCP ID No. NP-V2EHUWO907), which authorizes us to manufacture and sell our Hourglass™ products throughout Canada.

Cost of goods sold for the six months ended June 30, 2022 was $234,311 as compared to $580,598 for the corresponding period in 2021, a decrease of $346,287, or 59.6%. Included in cost of goods sold are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. When inspecting inventory this quarter, we found some inventory was damaged, which necessitated a $68,500 reduction in inventory. Most of the product was salvageable and will be ready for resale in August 2022.

Our resulting gross loss for the six months ended June 30, 2022 was $204,600 as compared with the gross loss of $147,294 for the corresponding period in 2021, an increase of $57,306, or 38.9%. The increase was a result of the general decrease in sales and the associated costs of goods sold.

Sales expense for the six months ended June 30, 2022 was $0 compared to the $1,960 for 2021, a decrease of $1,960. The decrease was a result of sales being done internally or online. Stock based compensation for the three months ended June 30, 2022 were $195,905 compared to $239,044 for 2021, a decrease of $43,139, or 18.0%. Stock option expenses for the six months ended June 30, 2022 were $20,998 compared to $32,877 for 2021, a decrease of $11,876, or 36.1%. General and administrative expenses for the six months ended June 30, 2022 were $750,612 compared to $658,737 for 2021, an increase of $91,875, or 13.9%. This increase was due to the evaluation of the collectability of our accounts receivable. Based on the aging and likelihood of collectability, an allowance for doubtful accounts was created in the amount of $257,594.

Our resulting net loss from operations for the six months ended June 30, 2022 was $1,172,115 as compared to $1,079,912 for the corresponding period for 2021, an increase of $92,203, or 8.5%. Change in value of derivatives gain for the six months ended June 30, 2022 was $123,894 as compared to $77,333 for 2021, an increase of $46,561, or 60.2%.

Our resulting net loss attributable to Grapefruit USA, Inc. and subsidiary for the six months ended June 30, 2022 was $1,849,495 as compared to $2,763,327 for the corresponding period for 2021, a decrease of $913,832, or 33.1%.

Liquidity and Capital Resources

Our cash position decreased to $5,035 as of June 30, 2022 from $9,095 as of December 31, 2021. Our total current assets decreased to $404,651 as of June 30, 2021, from $767,322 as of December 31, 2021.

Our total current liabilities decreased to $7,281,488 as of June 30, 2022 from $7,703,573 as of December 31, 2021.

During the six months ended June 30, 2022, we used $281,394 of net cash for operating activities, as compared to cash used by operations of $807,164 used during the six months ended June 30, 2021. Net cash used in investing activities during the six months ended June 30, 2022 was $0, as compared to $56,679 during the six months ended June 30, 2021. Net cash provided by financing activities during the six months ended June 30, 2022 was $277,344, as compared to $752,103 during the six months ended June 30, 2021.

We expect our working capital requirements in the next year to be met primarily by the proceeds of issuance of debt, equity and other securities to our existing creditors, shareholders, and other investors, as well as from cash flow from operations. We also expect that, as in the past, significant amounts of our convertible debt with a major lender will be converted into equity. We expect to need additional working capital from outside sources to cover our anticipated operating expenses. There is no assurance that the Company will be able to raise sufficient additional capital or financing to continue in business or to effectively execute its business plan.

COVID-19 Impact

The COVID-19 pandemic has had, and continues to have, a significant impact around the world, prompting governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of businesses, and quarantine and shelter-in-place orders. The COVID-19 pandemic has at times significantly curtailed global economic activity and caused significant volatility and disruption in global financial markets. The COVID-19 pandemic and the measures taken by many countries in response have affected and could in the future materially impact the Company’s business, results of operations and financial condition.

Certain of the Company’s outsourcing partners, component suppliers and logistical service providers have experienced disruptions during the COVID-19 pandemic, resulting in supply shortages. Similar disruptions could occur in the future.

Going Concern Qualification

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the ~~three~~six months ended ~~March~~June 3130, 2022, we we incurred a net loss of $~~484~~1,~~255~~849,495, had a working capital deficit of $76,~~395~~876,~~991~~837 and had an accumulated deficit of $1718,~~310~~675,~~419~~659 at ~~March~~June 3130, 2022. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and or obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

Item 4. Controls and Procedures

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive and financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

As of ~~March~~June 3130, 2022, our management assessed the effectiveness of our internal control over financial reporting using the criteria set ~~forth~~ forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). ~~Based~~ Based on this assessment, our management concluded that, as of ~~March~~June 3130, 2022, our internal control over financial reporting was effective ~~based~~ based on those criteria.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting through the date of this report or during the quarter ended ~~March~~June 3130, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This report does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

~~On March 8, 2022, Grapefruit USA, Inc~~None. was contacted by an attorney about outstanding litigation between Mentor Group, Inc. and Imagaing3, Inc. We estimate that Grapefruit will be required to settle for approximately $35,000. This debt is related to Imaging3, Inc.’s business activities which preceded Grapefruit’s acquisition of Imaging3, Inc.

Item 1A. Risk Factors

Smaller reporting companies are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the period covered by this quarterly report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

(a) Exhibits

EXHIBIT NO.		DESCRIPTION

31.1		Section 302 Certification of Chief Executive Officer
31.2		Section 302 Certification of Chief Financial Officer
32.1		Section 906 Certification
32.2		Section 906 Certification
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2528

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Bradley J. Yourist		Dated: ~~May~~August 2022, 2022
Bradley J. Yourist
Chief Executive Officer
/s/ Kenneth J. Biehl		Dated: ~~May~~August 2022, 2022
Kenneth J. Biehl
Chief Financial Officer

2629

Filing Compare · Grapefruit USA, Inc